ChemicalBook > CAS DataBase List > Regorafenib-13C-d3

Regorafenib-13C-d3

Product Name
Regorafenib-13C-d3
CAS No.
2126178-55-8
Chemical Name
Regorafenib-13C-d3
Synonyms
Regorafenib-13C-d3;4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-(methyl-13C-d3)-2-pyridinecarboxamide
CBNumber
CB92675548
Molecular Formula
C21H12ClD3F4N4O3
Formula Weight
486.842898134
MOL File
2126178-55-8.mol
More
Less

Regorafenib-13C-d3 Property

storage temp. 
Store at -20°C
solubility 
DMF: 30 mg/ml; DMSO: 30 mg/ml; Ethanol: 14 mg/ml
form 
A solid
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

N-Bromosuccinimide Price

Cayman Chemical
Product number
25486
Product name
Regorafenib-13C-d3
Purity
≥99% deuterated forms (d1-d3)
Packaging
500μg
Price
$242
Updated
2024/03/01
Cayman Chemical
Product number
25486
Product name
Regorafenib-13C-d3
Purity
≥99% deuterated forms (d1-d3)
Packaging
1mg
Price
$459
Updated
2024/03/01
AK Scientific
Product number
0135DY
Product name
4-[4-[[4-Chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-3-fluorophenoxy]-N-(trideuterio(113C)methyl)pyridine-2-carboxamide
Packaging
1mg
Price
$610
Updated
2021/12/16
More
Less

Regorafenib-13C-d3 Chemical Properties,Usage,Production

Description

Regorafenib-13C-d3 is intended for use as an internal standard for the quantification of regorafenib by GC- or LC-MS. Regorafenib is an orally bioavailable multi-kinase inhibitor with anticancer activity.1 It inhibits RET, C-RAF, VEGFR2, c-Kit, VEGFR1, and PDGFRβ with IC50 values of 1.5, 2.5, 4.2, 7, 13, and 22 nM, respectively. Regorafenib also inhibits B-RAF, VEGFR3, FGFR, and Tie2 (IC50s = 28, 46, 202, and 311 nM, respectively) as well as other kinases.1,2,3 In vivo, regorafenib (10 mg/kg) reduces tumor size in the MDA-MB-231 breast and 786-O renal cancer mouse xenograft models.1 It also reduces tumor microvessel area and inhibits tumor growth in a panel of mouse xenograft models. Formulations containing regorafenib have been used in the treatment of advanced gastrointestinal stromal tumors and metastatic colorectal cancer.

References

1. Wilhelm, S.M., Dumas, J., Adnane, L., et al. Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity Int. J. Cancer 129(1),245-255(2011).
2. Uitdehaag, J.C.M., de Roos, J.A.D.M., van Doornmalen, A.M., et al. Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use PLoS One 9(3),1-13(2014).
3. Ravi, S., and Singal, A.K. Regorafenib: An evidence-based review of its potential in patients with advanced liver cancer Core Evid. 9,81-87(2014).

Regorafenib-13C-d3 Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Regorafenib-13C-d3 Suppliers

CHINA 11 United States 2 Global 13
Shanghai Hongye Biotechnology Co. Ltd
Tel
400-9205774
Email
sales@glpbio.cn
Country
China
ProdList
6777
Advantage
58
Shenzhen Polymeri Biochemical Technology Co., Ltd.
Tel
+86-400-002-6226 +86-13028896684;
Email
sales@rrkchem.com
Country
China
ProdList
57423
Advantage
58
QUALITY CONTROL SOLUTIONS LTD.
Tel
0755-66853366; 13670046396
Email
ORDERS@QCSRM.COM
Country
China
ProdList
24342
Advantage
58
Nanjing Tengyi Biotechnology Co., Ltd
Tel
025-58851786 17714337195
Email
sales@tybiochem.com
Country
China
ProdList
6830
Advantage
58
Shanghai Yifei Biotechnology Co. , Ltd.
Tel
021-65675885 18964387627
Email
customer_service@efebio.com
Country
China
ProdList
11974
Advantage
58
TargetMol Chemicals Inc.
Tel
+8613564774135
Email
zijue.cai@tsbiochem.com
Country
United States
ProdList
19881
Advantage
58

2126178-55-8, Regorafenib-13C-d3Related Search:


  • Regorafenib-13C-d3
  • 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-(methyl-13C-d3)-2-pyridinecarboxamide
  • 2126178-55-8